Last year, Roche and Spark decided to discontinue development of two potential hemophilia A treatments in Spark's new product ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.

Governor Gavin Newsom announced March 21 that the Department of Health Care Services submitted an application to the federal Center for Medicaid and Medicaid Innovation at the Centers for Medicare & ...

The layoffs at the gene therapy company are part of restructuring of Spark Therapeutics by its owner, Roche Group.

Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...

GreenLight Biosciences, Inc., a Boston-based agtech company with lab, office and greenhouse space in RTP, has closed a Series C funding round, including a $25 million investment from a new investor, ...

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" ...

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death of a young man who died following treatment.

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...